文献速递临床试验与 GCP

Vutrisiran对转甲状腺素蛋白淀粉样变心肌病患者心脏结构与功能的影响:HELIOS-B试验的次要结局

Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.
PubMed 文献 · Nat Med · 2025-08-06

HELIOS-B随机临床试验的次要分析纳入654例转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)患者(93%为男性),比较vutrisiran与安慰剂对超声心动图心脏结构和功能指标的影响。治疗30个月后,与安慰剂组相比,vutrisiran减轻了左心室壁厚度和左心室质量指数的增加,并减缓了左心室射血分数、整体纵向应变和左心室每搏输出量的下降,同时降低了二尖瓣舒张早期血流速度与瓣环组织速度比值及舒张早期与晚期血流速度比值。这些超声心动图结果与vutrisiran的临床获益一致,提示其对ATTR-CM患者心脏结构和功能具有有利影响。

要点

  • 治疗30个月时,vutrisiran组左心室壁厚度最小二乘均值差异为-0.4 mm(95%CI -0.8至0.0,P=0.03),左心室质量指数差异为-10.6 g/m²(95%CI -18.0至-3.3,P<0.01)。
  • vutrisiran减缓左心室射血分数下降2.0%(95%CI 0.3至3.7,P=0.02),减缓整体纵向应变绝对值下降1.2%(95%CI 0.7至1.7,P<0.01),减缓左心室每搏输出量下降4.1 ml(95%CI 1.7至6.4,P<0.01)。
  • vutrisiran降低二尖瓣舒张早期血流速度与瓣环组织速度平均比值(差异-2.0,95%CI -2.9至-1.2,P<0.01)及舒张早期与晚期血流速度比值(差异-0.3,95%CI -0.6至-0.0,P=0.04)。

核心结论

  • 与临床获益一致,这些超声心动图结果表明vutrisiran对ATTR-CM患者的心脏结构和功能具有有利影响。

研究设计与样本

  • HELIOS-B随机临床试验的次要分析,纳入接受vutrisiran或安慰剂的ATTR-CM患者共654例(93%为男性)。

主要发现

  • 治疗30个月后,与安慰剂组相比,vutrisiran组左心室壁厚度最小二乘均值差异为-0.4 mm(95%CI -0.8至0.0,P=0.03),左心室质量指数差异为-10.6 g/m²(95%CI -18.0至-3.3,P<0.01)。
  • 与安慰剂组相比,vutrisiran组左心室射血分数差异为2.0%(95%CI 0.3至3.7,P=0.02),整体纵向应变绝对值差异为1.2%(95%CI 0.7至1.7,P<0.01),左心室每搏输出量差异为4.1 ml(95%CI 1.7至6.4,P<0.01)。
  • 与安慰剂组相比,vutrisiran组二尖瓣舒张早期血流速度与瓣环组织速度平均比值差异为-2.0(95%CI -2.9至-1.2,P<0.01),舒张早期与晚期血流速度比值差异为-0.3(95%CI -0.6至-0.0,P=0.04)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the HELIOS-B randomized clinical trial, the RNA interference therapeutic agent vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events among patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). In this secondary analysis of HELIOS-B, we evaluated vutrisiran's effects on echocardiographic measures of cardiac structure and function in patients with ATTR-CM receiving vutrisiran or placebo (n = 654, 93% men). At 30 months after treatment, as compared to the placebo group, vutrisiran treatment attenuated increases in mean left ventricular (LV) wall thickness (least squares mean difference: -0.4 mm; 95% confidence interval (CI): -0.8, 0.0; P = 0.03) and LV mass index (-10.6 g m-2; 95% CI: -18.0, -3.3; P < 0.01). Vutrisiran treatment also attenuated declines in LV ejection fraction (2.0%; 95% CI: 0.3, 3.7; P = 0.02), absolute global longitudinal strain (1.2%; 95% CI: 0.7, 1.7; P < 0.01) and LV stroke volume (4.1 ml; 95% CI: 1.7, 6.4; P < 0.01), and decreased both the average ratio of early diastolic transmitral flow velocity to early diastolic mitral annular tissue velocity (-2.0; 95% CI: -2.9, -1.2; P < 0.01) and the early to late diastolic transmitral flow velocities ratio (-0.3; 95% CI: -0.6, -0.0; P = 0.04), as compared to placebo. Consistent with its clinical benefits, these echocardiographic findings indicate favorable effects of vutrisiran on cardiac structure and function in patients with ATTR-CM. ClinicalTrials.gov registration: NCT04153149 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Jering KS, Fontana M, Lairez O, et al. Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial. Nat Med. 2025. PMID: 40770082. doi:10.1038/s41591-025-03851-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。